MedTrace Logo

NF-κB Inhibition in Amyotrophic Lateral Sclerosis

NCT05031351 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-06-06

No results posted yet for this study

Summary

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).

Conditions

Interventions

DRUG

Withania somnifera

Nuclear Factor Kappa Beta Inhibitor

DRUG

Placebo

Placebo Comparator

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Agessandro Abrahao, MD, MSc · Sunnybrook Research Institute, University of Toronto

  • Lorne Zinman, MD, MSc · Sunnybrook Research Institute, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2022-07-31
Completion
2022-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031351 on ClinicalTrials.gov